<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308236">
  <stage>Registered</stage>
  <submitdate>16/07/2009</submitdate>
  <approvaldate>30/10/2012</approvaldate>
  <actrnumber>ACTRN12612001145897</actrnumber>
  <trial_identification>
    <studytitle>Does Vitamin D supplementation in pregnancy improve maternal glucose metabolism or prevent gestational diabetes?</studytitle>
    <scientifictitle>Effect of high-dose versus low-dose vitamin D supplementation in pregnancy on maternal glucose metabolism and the risk of gestational diabetes.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gestational Diabetes</healthcondition>
    <healthcondition>Pregnancy</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Normal metabolism and endocrine development and function</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Antenatal care</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Pregnant women will be randomly allocated to take high-dose vitamin D supplementation (5000IU/day) or standard dose pregnancy vitamin supplementation (400 IU vitamin D daily), administered as an oral capsule, from the time of the first antenatal clinic visit (around 12 weeks gestation) until delivery.</interventions>
    <comparator>Standard dose vitamin D supplementation (as in commonly used pregnancy multivitamin preparations)</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Maternal glucose metabolism in late second trimester (26-28 weeks gestation) assessed by glucose tolerance test (blood analysis after ingestion of 75g oral glucose).</outcome>
      <timepoint>26-28 weeks gestation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Diagnosis of Gestational Diabetes, determined by an oral Glucose Tolerance Test (blood analysis after ingestion of 75g oral glucose) performed at 26-28 weeks gestation, or other evidence of hyperglycaemia recorded throughout pregnancy.</outcome>
      <timepoint>End of pregnancy</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Infant weight at birth, infant length (assessed with a newborn stadiometer) and head circumference.</outcome>
      <timepoint>First week of life</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Pregnancy, less than 20 weeks gestation at recruitment.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Known diabetes
Calcium metabolic disorder
Multiple pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients will be recruited at their first antenatal clinic visit.  Baseline tests will exclude pre-existing diabetes, hypercalcaemia or vitamin D toxicity.  Treatment will be stratified according to baseline serum vitamin D levels and randomized by the trial pharmecist using opaque envelopes containing a treatment allocation.  Patient, treating clinician and researchers will remain blinded to treatment group.</concealment>
    <sequence>Opaque envelopes containing treatment allocation to one of 2 dose levels of Vitamin D (identical capsules).  Permuted block randomisation.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>10/02/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2145</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Westmead Hospital</primarysponsorname>
    <primarysponsoraddress>Hawkesbury Road
Westmead NSW 2145</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Westmead Hospital</fundingname>
      <fundingaddress>Hawkesbury Road
Westmead NSW 2145</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Western Sydney</sponsorname>
      <sponsoraddress>University of Western Sydney
Locked Bag 1797
Penrith South DC
NSW 2751</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will determine whether taking additional Vitamin D supplementation in pregnancy, above that contained in conventional pregnancy vitamin tablets, improves a woman's glucose metabolism and prevents the development of gestational diabetes, a common complication of pregnancy in Australia.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Western Sydney Local Health District Human Research Ethics Committee</ethicname>
      <ethicaddress>Westmead Hospital
Hawkesbury Road
Westmead NSW 2145</ethicaddress>
      <ethicapprovaldate>7/10/2009</ethicapprovaldate>
      <hrec>AU RED HREC/09/WMEAD/54  HREC2009/4/4.1 (2953)</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mark McLean</name>
      <address>Professor Mark McLean
University of Western Sydney - Blacktown Clinical School
Blacktown Hospital
PO Box 6105 BLACKTOWN NSW 2148</address>
      <phone>+61 2 9851 6073</phone>
      <fax>+61 2 9851 6050</fax>
      <email>m.mclean@uws.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mark McLean</name>
      <address>Professor Mark McLean
University of Western Sydney - Blacktown Clinical School
Blacktown Hospital
PO Box 6105 BLACKTOWN NSW 2148</address>
      <phone>+61 2 9851 6073</phone>
      <fax>+61 2 9851 6050</fax>
      <email>m.mclean@uws.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mark McLean</name>
      <address>Professor Mark McLean
University of Western Sydney - Blacktown Clinical School
Blacktown Hospital
PO Box 6105 BLACKTOWN NSW 2148</address>
      <phone>+61 2 9851 6073</phone>
      <fax>+61 2 9851 6050</fax>
      <email>m.mclean@uws.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>